Eledon Unveils BESTOW Data, Phase III Launch Plans and FDA Timeline
Eledon Pharmaceuticals presented updated BESTOW study data for its Tego immunotherapy and outlined plans to initiate a global Phase III trial. Company executives also provided an FDA submission timeline contingent on completion of the pivotal study.
1. Conference Overview
Eledon Pharmaceuticals presented updated data from the BESTOW study of its lead candidate Tego at a recent industry conference. Executives detailed plans to launch a global Phase III program and outlined an FDA submission timeline that follows pivotal study completion.
Related News
INTU
Intuit to Launch AI-Driven Platforms in August, Cuts 17% Workforce to Fund Growth
INTU•
GOOGL
Google Plans Own Inference Chips as Nvidia Forecasts $91B Revenue, $80B Buyback
GOOGL•
SMCZ
SMCZ Inverse ETF Plunges 18.5% to $13.10 on Semiconductor Strength
SMCZ•
VBCG
Vanguard’s BondBuilder ETFs Gather $242M in Two Months with 0.08% Fees
VBCG•
WMT
Walmart Set for Q1 EPS of $0.66 on $175B Revenue; Value Outlook Tempered
WMT•
Sources
F